The University of Southampton
University of Southampton Institutional Repository

Lurasidone in children and adolescents: systematic review and case report

Lurasidone in children and adolescents: systematic review and case report
Lurasidone in children and adolescents: systematic review and case report
Objective: To perform a systematic review of studies of lurasidone in children and/or adolescents and to present a case report aimed to add further insights into its use in clinical practice with youth. Methods: We searched the following databases for empirical studies, of any design, focusing on the pharmacokinetics, efficacy, or safety of lurasidone in children and/or adolescents: Pubmed (Medline), OVID (PsycInfo, EMBASE+EMBASE classic, OVID Medline), Web of Knowledge, and ClinicalTrials.gov (last search January 23, 2018). Results: From a pool of 301 potentially relevant references, we retained 12 pertinent studies (reported in 28 references), including 1 pharmacokinetics study, 1 double blind randomized controlled trial (RCT) for bipolar depression (BD) with 1 related interim analysis study of its extension phase and 1 related external posterior predictive check study, 1 double blind RCT for schizophrenia with 3 related interim analyses of its extension phase, 1 RCT and 1 case report for autism spectrum disorder, and 2 open-label studies focusing on a variety of disorders. Overall, these studies show that lurasidone is significantly more efficacious than placebo, with moderate effect sizes, and is well tolerated for BD and schizophrenia in youth. Published studies in youth have in general used doses up to 80 mg/day. Our case report suggests that high doses of lurasidone (148 mg/day) were well tolerated and might have contributed to substantial functional improvement in a 14-year old girl with psychosis and a previous history of anorexia nervosa, who had not responded to previous antipsychotics (olanzapine, risperidone, aripiprazole). Conclusions: There is increasing evidence that lurasidone may be moderately effective and well tolerated for the treatment of BD and psychosis in youth and may have procognitive effects. Our case report suggests that future RCTs should assess the efficacy and tolerability of high doses (>80 mg/day) of lurasidone in youth.
1044-5463
Channing, Jonathan
f07bde2a-b782-4046-8920-e1ed3ac349b5
Mitchell, Mary
8d5d2d45-4ae4-4996-af2a-0090994112ae
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Channing, Jonathan
f07bde2a-b782-4046-8920-e1ed3ac349b5
Mitchell, Mary
8d5d2d45-4ae4-4996-af2a-0090994112ae
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb

Channing, Jonathan, Mitchell, Mary and Cortese, Samuele (2018) Lurasidone in children and adolescents: systematic review and case report. Journal of Child and Adolescent Psychopharmacology. (doi:10.1089/cap.2018.0046).

Record type: Article

Abstract

Objective: To perform a systematic review of studies of lurasidone in children and/or adolescents and to present a case report aimed to add further insights into its use in clinical practice with youth. Methods: We searched the following databases for empirical studies, of any design, focusing on the pharmacokinetics, efficacy, or safety of lurasidone in children and/or adolescents: Pubmed (Medline), OVID (PsycInfo, EMBASE+EMBASE classic, OVID Medline), Web of Knowledge, and ClinicalTrials.gov (last search January 23, 2018). Results: From a pool of 301 potentially relevant references, we retained 12 pertinent studies (reported in 28 references), including 1 pharmacokinetics study, 1 double blind randomized controlled trial (RCT) for bipolar depression (BD) with 1 related interim analysis study of its extension phase and 1 related external posterior predictive check study, 1 double blind RCT for schizophrenia with 3 related interim analyses of its extension phase, 1 RCT and 1 case report for autism spectrum disorder, and 2 open-label studies focusing on a variety of disorders. Overall, these studies show that lurasidone is significantly more efficacious than placebo, with moderate effect sizes, and is well tolerated for BD and schizophrenia in youth. Published studies in youth have in general used doses up to 80 mg/day. Our case report suggests that high doses of lurasidone (148 mg/day) were well tolerated and might have contributed to substantial functional improvement in a 14-year old girl with psychosis and a previous history of anorexia nervosa, who had not responded to previous antipsychotics (olanzapine, risperidone, aripiprazole). Conclusions: There is increasing evidence that lurasidone may be moderately effective and well tolerated for the treatment of BD and psychosis in youth and may have procognitive effects. Our case report suggests that future RCTs should assess the efficacy and tolerability of high doses (>80 mg/day) of lurasidone in youth.

Text
180403_Lurasidone_Syst_rev_case_MAIN TEXT - Accepted Manuscript
Download (67kB)

More information

Accepted/In Press date: 4 June 2018
e-pub ahead of print date: 13 July 2018

Identifiers

Local EPrints ID: 422912
URI: http://eprints.soton.ac.uk/id/eprint/422912
ISSN: 1044-5463
PURE UUID: 2091352f-3999-48d4-b0a6-83406b63a0d6
ORCID for Samuele Cortese: ORCID iD orcid.org/0000-0001-5877-8075

Catalogue record

Date deposited: 07 Aug 2018 16:31
Last modified: 16 Mar 2024 06:54

Export record

Altmetrics

Contributors

Author: Jonathan Channing
Author: Mary Mitchell
Author: Samuele Cortese ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×